1
|
Fretellier N, Rasschaert M, Bocanegra J, Robert P, Factor C, Seron A, Idée JM, Corot C. Safety and Gadolinium Distribution of the New High-Relaxivity Gadolinium Chelate Gadopiclenol in a Rat Model of Severe Renal Failure. Invest Radiol 2021; 56:826-836. [PMID: 34091462 DOI: 10.1097/rli.0000000000000793] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
OBJECTIVE The aim of this study was to investigate the toxicological profile of gadopiclenol, a new high-relaxivity macrocyclic gadolinium-based contrast agent (GBCA), in renally impaired rats, in comparison with 2 other macrocyclic GBCAs, gadoterate meglumine and gadobutrol, and 1 linear and nonionic GBCA, gadodiamide. METHODS Renal failure was induced by adding 0.75% wt/wt adenine to the diet for 3 weeks. During the second week of adenine-enriched diet, the animals (n = 8/group × 5 groups) received 5 consecutive intravenous injections of GBCA at 2.5 mmol/kg per injection, resulting in a cumulative dose of 12.5 mmol/kg or saline followed by a 3-week treatment-free period after the last injection. The total (elemental) gadolinium (Gd) concentration in different tissues (brain, cerebellum, femoral epiphysis, liver, skin, heart, kidney, spleen, plasma, urine, and feces) was measured by inductively coupled plasma mass spectrometry. Transmission electron microscopy (and electron energy loss spectroscopy analysis of metallic deposits) was used to investigate the presence and localization of Gd deposits in the skin. Relaxometry was used to evaluate the presence of dissociated Gd in the skin, liver, and bone. Skin histopathology was performed to investigate the presence of nephrogenic systemic fibrosis-like lesions. RESULTS Gadodiamide administrations were associated with high morbidity-mortality but also with macroscopic and microscopic skin lesions in renally impaired rats. No such effects were observed with gadopiclenol, gadoterate, or gadobutrol. Overall, elemental Gd concentrations were significantly higher in gadodiamide-treated rats than in rats treated with the other GBCAs for all tissues except the liver (where no significant difference was found with gadopiclenol) and the kidney and the heart (where statistically similar Gd concentrations were observed for all GBCAs). No plasma biochemical abnormalities were observed with gadopiclenol or the control GBCAs. Histopathology revealed a normal skin structure in the rats treated with gadopiclenol, gadoterate, and gadobutrol, contrary to those treated with gadodiamide. No evidence of Gd deposits on collagen fibers and inclusions in fibroblasts was found with gadopiclenol and its macrocyclic controls, unlike with gadodiamide. Animals of all test groups had Gd-positive lysosomal inclusions in the dermal macrophages. However, the textures differed for the different products (speckled texture for gadodiamide and rough-textured appearance for the 2 tested macrocyclic GBCAs). CONCLUSIONS No evidence of biochemical toxicity or pathological abnormalities of the skin was observed, and similar to other macrocyclic GBCAs, gadoterate and gadobutrol, tissue retention of Gd was found to be low (except in the liver) in renally impaired rats treated with the new high-relaxivity GBCA gadopiclenol.
Collapse
Affiliation(s)
- Nathalie Fretellier
- From the Research and Innovation Department, Guerbet, Aulnay-sous-Bois, France
| | | | | | | | | | | | | | | |
Collapse
|
2
|
Smith HJ. The history of magnetic resonance imaging and its reflections in Acta Radiologica. Acta Radiol 2021; 62:1481-1498. [PMID: 34657480 DOI: 10.1177/02841851211050857] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
The first reports in Acta Radiologica on magnetic resonance imaging (MRI) were published in 1984, four years after the first commercial MR scanners became available. For the first two years, all MR papers originated from the USA. Nordic contributions started in 1986, and until 2020, authors from 44 different countries have published MR papers in Acta Radiologica. Papers on MRI have constituted, on average, 30%-40% of all published original articles in Acta Radiologica, with a high of 49% in 2019. The MR papers published since 1984 document tremendous progress in several areas such as magnet and coil design, motion compensation techniques, faster image acquisitions, new image contrast, contrast-enhanced MRI, functional MRI, and image analysis. In this historical review, all of these aspects of MRI are discussed and related to Acta Radiologica papers.
Collapse
Affiliation(s)
- Hans-Jørgen Smith
- Department of Radiology and Nuclear Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| |
Collapse
|
3
|
Abstract
This review focuses on the trends in contrast media (CM) research published in Acta Radiologica during the last 100 years, since the first edition in 1921. The main topics covered are the developments of iodine- and gadolinium-based CM. Other topics include manganese-based CM for magnetic resonance imaging (MRI) and barium for the investigation of the alimentary tract. From a historic point of view, special CM for use in cholegraphy and myelography are addressed in the review. Today, these imaging procedures are obsolete due to the development of computed tomography, MRI, and ultrasound. The historical use of radioactive thorium-based CM for angiography is also addressed. Furthermore, publications on adverse reactions to CM are reviewed.
Collapse
Affiliation(s)
- Yousef W Nielsen
- Department of Radiology, University Hospital Herlev and Gentofte, Copenhagen, Denmark
| | - Henrik S Thomsen
- Department of Radiology, University Hospital Herlev and Gentofte, Copenhagen, Denmark
| |
Collapse
|
4
|
Critical Questions Regarding Gadolinium Deposition in the Brain and Body After Injections of the Gadolinium-Based Contrast Agents, Safety, and Clinical Recommendations in Consideration of the EMA's Pharmacovigilance and Risk Assessment Committee Recommendation for Suspension of the Marketing Authorizations for 4 Linear Agents. Invest Radiol 2018; 52:317-323. [PMID: 28368880 DOI: 10.1097/rli.0000000000000374] [Citation(s) in RCA: 124] [Impact Index Per Article: 20.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
For magnetic resonance, the established class of intravenous contrast media is the gadolinium-based contrast agents. In the 3 decades since initial approval, these have proven in general to be very safe for human administration. However, in 2006, a devastating late adverse reaction to administration of the less stable gadolinium-based contrast agents was identified, nephrogenic systemic fibrosis. The result of actions taken by the European Medicines Agency and the US Food and Drug Administration, stratifying the agents by risk and contraindicating specific agents in severe renal dysfunction, has led to no new cases being identified in North America or Europe. Subsequently, in 2014, long-term deposition in the brain of gadolinium was first shown, after administration of 2 nonionic linear chelates, gadodiamide, and gadopentetate dimeglumine. This has led to an intense focus on the question of in vivo distribution, possible dechelation, and subsequent deposition of gadolinium, together with substantial clarification of the phenomenon as well as stratification of the agents on this basis. This review focuses on 8 critical questions regarding gadolinium deposition in the brain and body, with the answers and discussion therein important for future regulatory decisions and clinical practice. It is now clear that dechelation of gadolinium occurs in vivo with the linear agents and is responsible for this phenomenon, with key experts in the field recommending, except where there is no suitable alternative, a shift in clinical practice from the linear to macrocyclic agents. In addition, on March 10, 2017, the Pharmacovigilance and Risk Assessment Committee of the European Medicines Agency recommended suspension of the marketing authorization for 4 linear gadolinium contrast agents-specifically Omniscan, Optimark, Magnevist, and MultiHance (gadodiamide, gadoversetamide, gadopentetate dimeglumine, and gadobenate dimeglumine)-for intravenous injection. Cited in the report was convincing evidence of gadolinium deposition in the brain months after injection of these linear agents. Primovist/Eovist (gadoxetic acid disodium) will remain available, being used at a lower dose for liver imaging, because it meets an important diagnostic need. In addition, a formulation of Magnevist for intra-articular injection will remain available because of its very low gadolinium concentration.
Collapse
|
5
|
Scala M, Koob M, de Buttet S, Bourrinet P, Felices M, Jurkiewicz E. A Pharmacokinetics, Efficacy, and Safety Study of Gadoterate Meglumine in Pediatric Subjects Aged Younger Than 2 Years. Invest Radiol 2018; 53:70-79. [PMID: 28906338 PMCID: PMC5768226 DOI: 10.1097/rli.0000000000000412] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2017] [Accepted: 07/22/2017] [Indexed: 01/31/2023]
Abstract
OBJECTIVES The primary objective of this study was to investigate the pharmacokinetic profile of gadoterate meglumine in pediatric patients younger than 2 years; the secondary objectives were to document its efficacy and safety. MATERIAL AND METHODS This was a Phase IV open-label, prospective study conducted in 9 centers (4 countries). Forty-five patients younger than 2 years with normal estimated glomerular filtration rate and scheduled to undergo routine gadolinium-enhanced magnetic resonance imaging (MRI) of any organ were included and received a single intravenous injection of gadoterate meglumine (0.1 mmol/kg). To perform the population pharmacokinetics analysis, 3 blood samples per subject were drawn during 3 time windows at time points allocated by randomization. RESULTS Gadoterate meglumine concentrations were best fitted using a 2-compartmental model with linear elimination from central compartment. The median total clearance adjusted to body weight was estimated at 0.06 L/h per kg and increased with estimated glomerular filtration rate according to a power model. The median volume of distribution at steady state (Vss) adjusted to body weight was estimated at 0.047 L/kg. Estimated median terminal half-life (t1/2β) was 1.35 h, and the median systemic exposure (area under the curve) was 1591 μmol h/L. Efficacy was assessed by comparing precontrast +postcontrast images to precontrast images in a subset of 28 subjects who underwent an MRI examination of brain, spine, and associated tissues. A total of 28 lesions were identified and analyzed in 15 subjects with precontrast images versus 30 lesions in 16 subjects with precontrast + postcontrast images. Lesion visualization was improved with a mean (SD) increase in scores at subject level of 0.7 (1.0) for lesion border delineation, 0.9 (1.6) for internal morphology, and 3.1 (3.2) for contrast enhancement. Twenty-six adverse events occurred postinjection in 13 subjects (28.9%), including 3 serious reported in 1 subject (2.2%). One subject (2.2%) experienced 1 rash of moderate intensity considered as related to gadoterate meglumine. CONCLUSIONS The pharmacokinetic profile of gadoterate meglumine after a single intravenous injection of 0.1 mmol/kg was appropriately described in newborns and infants younger than 2 years, for whom no dose adjustment is required. The improved efficacy of gadoterate meglumine for contrast-enhanced MRI examination of brain, spine, and associated tissues, as well as its good safety profile, was also demonstrated in this population.
Collapse
Affiliation(s)
- Mario Scala
- From the *Med. Campus IV–Institute of Pediatric and Gynecologic Radiology and Med. Campus III–Central Radiology Institute, Kepler University Hospital, Linz, Austria; †Pediatric Radiology, Hautepierre Hospital, Strasbourg, France; ‡Guerbet, Roissy CDG Cedex, France; §Phinc, Massy, France; and ∥Department of Diagnostic Imaging, Children's Memorial Health Institute, Warszawa, Poland
| | - Meriam Koob
- From the *Med. Campus IV–Institute of Pediatric and Gynecologic Radiology and Med. Campus III–Central Radiology Institute, Kepler University Hospital, Linz, Austria; †Pediatric Radiology, Hautepierre Hospital, Strasbourg, France; ‡Guerbet, Roissy CDG Cedex, France; §Phinc, Massy, France; and ∥Department of Diagnostic Imaging, Children's Memorial Health Institute, Warszawa, Poland
| | - Sophie de Buttet
- From the *Med. Campus IV–Institute of Pediatric and Gynecologic Radiology and Med. Campus III–Central Radiology Institute, Kepler University Hospital, Linz, Austria; †Pediatric Radiology, Hautepierre Hospital, Strasbourg, France; ‡Guerbet, Roissy CDG Cedex, France; §Phinc, Massy, France; and ∥Department of Diagnostic Imaging, Children's Memorial Health Institute, Warszawa, Poland
| | - Philippe Bourrinet
- From the *Med. Campus IV–Institute of Pediatric and Gynecologic Radiology and Med. Campus III–Central Radiology Institute, Kepler University Hospital, Linz, Austria; †Pediatric Radiology, Hautepierre Hospital, Strasbourg, France; ‡Guerbet, Roissy CDG Cedex, France; §Phinc, Massy, France; and ∥Department of Diagnostic Imaging, Children's Memorial Health Institute, Warszawa, Poland
| | - Mathieu Felices
- From the *Med. Campus IV–Institute of Pediatric and Gynecologic Radiology and Med. Campus III–Central Radiology Institute, Kepler University Hospital, Linz, Austria; †Pediatric Radiology, Hautepierre Hospital, Strasbourg, France; ‡Guerbet, Roissy CDG Cedex, France; §Phinc, Massy, France; and ∥Department of Diagnostic Imaging, Children's Memorial Health Institute, Warszawa, Poland
| | - Elzbieta Jurkiewicz
- From the *Med. Campus IV–Institute of Pediatric and Gynecologic Radiology and Med. Campus III–Central Radiology Institute, Kepler University Hospital, Linz, Austria; †Pediatric Radiology, Hautepierre Hospital, Strasbourg, France; ‡Guerbet, Roissy CDG Cedex, France; §Phinc, Massy, France; and ∥Department of Diagnostic Imaging, Children's Memorial Health Institute, Warszawa, Poland
| |
Collapse
|
6
|
Forslin Y, Shams S, Hashim F, Aspelin P, Bergendal G, Martola J, Fredrikson S, Kristoffersen-Wiberg M, Granberg T. Retention of Gadolinium-Based Contrast Agents in Multiple Sclerosis: Retrospective Analysis of an 18-Year Longitudinal Study. AJNR Am J Neuroradiol 2017; 38:1311-1316. [PMID: 28495943 DOI: 10.3174/ajnr.a5211] [Citation(s) in RCA: 43] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2016] [Accepted: 03/03/2017] [Indexed: 01/06/2023]
Abstract
BACKGROUND AND PURPOSE Gadolinium-based contrast agents have been associated with lasting high T1-weighted signal intensity in the dentate nucleus and globus pallidus, with histopathologically confirmed gadolinium retention. We aimed to longitudinally investigate the relationship of multiple gadolinium-based contrast agent administrations to the Signal Intensity Index in the dentate nucleus and globus pallidus and any associations with cognitive function in multiple sclerosis. MATERIALS AND METHODS The Signal Intensity Index in the dentate nucleus and globus pallidus was retrospectively evaluated on T1-weighted MR imaging in an 18-year longitudinal cohort study of 23 patients with MS receiving multiple gadolinium-based contrast agent administrations and 23 healthy age- and sex-matched controls. Participants also underwent comprehensive neuropsychological testing. RESULTS Patients with MS had a higher Signal Intensity Index in the dentate nucleus (P < .001), but not in the globus pallidus (P = .19), compared with non-gadolinium-based contrast agent-exposed healthy controls by an unpaired t test. Increasing numbers of gadolinium-based contrast agent administrations were associated with an increased Signal Intensity Index in the dentate nucleus (β = 0.45, P < .001) and globus pallidus (β = 0.60, P < .001). This association remained stable with corrections for the age, disease duration, and physical disability for both the dentate nucleus (β = 0.43, P = .001) and globus pallidus (β = 0.58, P < .001). An increased Signal Intensity Index in the dentate nucleus among patients with MS was associated with lower verbal fluency scores, which remained significant after correction for several aspects of disease severity (β = -0.40 P = .013). CONCLUSIONS Our data corroborate previous reports of lasting gadolinium retention in brain tissues. An increased Signal Intensity Index in the dentate nucleus and globus pallidus was associated with lower verbal fluency, which does not prove causality but encourages further studies on cognition and gadolinium-based contrast agent administration.
Collapse
Affiliation(s)
- Y Forslin
- From the Departments of Clinical Science Intervention and Technology (Y.F., S.S., F.H., P.A., G.B., J.M., M.K.-W., T.G.) .,Radiology (Y.F., S.S., F.H., P.A., G.B., J.M., M.K.-W., T.G.)
| | - S Shams
- From the Departments of Clinical Science Intervention and Technology (Y.F., S.S., F.H., P.A., G.B., J.M., M.K.-W., T.G.).,Radiology (Y.F., S.S., F.H., P.A., G.B., J.M., M.K.-W., T.G.)
| | - F Hashim
- From the Departments of Clinical Science Intervention and Technology (Y.F., S.S., F.H., P.A., G.B., J.M., M.K.-W., T.G.).,Radiology (Y.F., S.S., F.H., P.A., G.B., J.M., M.K.-W., T.G.)
| | - P Aspelin
- From the Departments of Clinical Science Intervention and Technology (Y.F., S.S., F.H., P.A., G.B., J.M., M.K.-W., T.G.).,Radiology (Y.F., S.S., F.H., P.A., G.B., J.M., M.K.-W., T.G.)
| | - G Bergendal
- From the Departments of Clinical Science Intervention and Technology (Y.F., S.S., F.H., P.A., G.B., J.M., M.K.-W., T.G.).,Radiology (Y.F., S.S., F.H., P.A., G.B., J.M., M.K.-W., T.G.).,Neurology (G.B., S.F.)
| | - J Martola
- From the Departments of Clinical Science Intervention and Technology (Y.F., S.S., F.H., P.A., G.B., J.M., M.K.-W., T.G.).,Radiology (Y.F., S.S., F.H., P.A., G.B., J.M., M.K.-W., T.G.)
| | - S Fredrikson
- Neurology (G.B., S.F.).,Clinical Neuroscience (S.F.), Karolinska Institutet, Stockholm, Sweden
| | - M Kristoffersen-Wiberg
- From the Departments of Clinical Science Intervention and Technology (Y.F., S.S., F.H., P.A., G.B., J.M., M.K.-W., T.G.).,Radiology (Y.F., S.S., F.H., P.A., G.B., J.M., M.K.-W., T.G.)
| | - T Granberg
- From the Departments of Clinical Science Intervention and Technology (Y.F., S.S., F.H., P.A., G.B., J.M., M.K.-W., T.G.).,Radiology (Y.F., S.S., F.H., P.A., G.B., J.M., M.K.-W., T.G.)
| |
Collapse
|
7
|
Radbruch A, Haase R, Kieslich PJ, Weberling LD, Kickingereder P, Wick W, Schlemmer HP, Bendszus M. No Signal Intensity Increase in the Dentate Nucleus on Unenhanced T1-weighted MR Images after More than 20 Serial Injections of Macrocyclic Gadolinium-based Contrast Agents. Radiology 2016; 282:699-707. [PMID: 27925871 DOI: 10.1148/radiol.2016162241] [Citation(s) in RCA: 93] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Purpose To determine the effect of more than 20 serial injections of macrocyclic gadolinium-based contrast agents (GBCAs) on the signal intensity (SI) of the dentate nucleus (DN) on unenhanced T1-weighted magnetic resonance (MR) images. Materials and Methods In this retrospective, institutional review board-approved study, 33 patients who underwent at least 20 consecutive MR imaging examinations (plus an additional MR imaging for reference) with the exclusive use of macrocyclic GBCAs gadoterate meglumine and gadobutrol were analyzed. SI ratio differences were calculated for DN-to-pons and DN-to-middle cerebellar peduncle (MCP) ratios by subtracting the SI ratio at the first MR imaging examination from the SI ratio at the last MR imaging examination. One-sample t tests were used to examine if the SI ratio differences differed from 0, and Bayes factors were calculated to quantify the strength of evidence for each test. Results Patients underwent a mean of 23.03 ± (standard deviation) 4.20 GBCA administrations (mean accumulated dose, 491.21 mL ± 87.04 of a 0.5 M GBCA solution) with an average of 12.09 weeks ± 2.16 between every administration. Both ratio differences did not differ significantly from 0 (DN-to-pons ratio: -0.0032 ± 0.0154, P = .248; DN-to-MCP ratio: -0.0011 ± 0.0093, P = .521), and one-sided Bayes factors provided substantial to strong evidence against an SI ratio increase (Bayes factor for DN-to-pons ratio = 0.09 and that for DN-to-MCP ratio = 0.12). Conclusion The study indicates that 20 or more serial injections of macrocyclic GBCAs administered with on average 3 months between each injection are not associated with an SI increase in the DN. © RSNA, 2016.
Collapse
Affiliation(s)
- Alexander Radbruch
- From the Department of Neuroradiology (A.R., R.H., L.D.W., P.K., M.B.) and Neurology Clinic (W.W.), University of Heidelberg Medical Center, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany; Department of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany (A.R., R.H., L.D.W., H.P.S.); German Cancer Consortium (DKTK), Heidelberg, Germany (A.R., R.H., L.D.W.); Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University Duisburg-Essen, Essen, Germany (A.R.); and Department of Psychology, University of Mannheim, Mannheim, Germany (P.J.K.)
| | - Robert Haase
- From the Department of Neuroradiology (A.R., R.H., L.D.W., P.K., M.B.) and Neurology Clinic (W.W.), University of Heidelberg Medical Center, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany; Department of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany (A.R., R.H., L.D.W., H.P.S.); German Cancer Consortium (DKTK), Heidelberg, Germany (A.R., R.H., L.D.W.); Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University Duisburg-Essen, Essen, Germany (A.R.); and Department of Psychology, University of Mannheim, Mannheim, Germany (P.J.K.)
| | - Pascal J Kieslich
- From the Department of Neuroradiology (A.R., R.H., L.D.W., P.K., M.B.) and Neurology Clinic (W.W.), University of Heidelberg Medical Center, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany; Department of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany (A.R., R.H., L.D.W., H.P.S.); German Cancer Consortium (DKTK), Heidelberg, Germany (A.R., R.H., L.D.W.); Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University Duisburg-Essen, Essen, Germany (A.R.); and Department of Psychology, University of Mannheim, Mannheim, Germany (P.J.K.)
| | - Lukas D Weberling
- From the Department of Neuroradiology (A.R., R.H., L.D.W., P.K., M.B.) and Neurology Clinic (W.W.), University of Heidelberg Medical Center, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany; Department of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany (A.R., R.H., L.D.W., H.P.S.); German Cancer Consortium (DKTK), Heidelberg, Germany (A.R., R.H., L.D.W.); Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University Duisburg-Essen, Essen, Germany (A.R.); and Department of Psychology, University of Mannheim, Mannheim, Germany (P.J.K.)
| | - Philipp Kickingereder
- From the Department of Neuroradiology (A.R., R.H., L.D.W., P.K., M.B.) and Neurology Clinic (W.W.), University of Heidelberg Medical Center, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany; Department of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany (A.R., R.H., L.D.W., H.P.S.); German Cancer Consortium (DKTK), Heidelberg, Germany (A.R., R.H., L.D.W.); Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University Duisburg-Essen, Essen, Germany (A.R.); and Department of Psychology, University of Mannheim, Mannheim, Germany (P.J.K.)
| | - Wolfgang Wick
- From the Department of Neuroradiology (A.R., R.H., L.D.W., P.K., M.B.) and Neurology Clinic (W.W.), University of Heidelberg Medical Center, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany; Department of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany (A.R., R.H., L.D.W., H.P.S.); German Cancer Consortium (DKTK), Heidelberg, Germany (A.R., R.H., L.D.W.); Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University Duisburg-Essen, Essen, Germany (A.R.); and Department of Psychology, University of Mannheim, Mannheim, Germany (P.J.K.)
| | - Heinz-Peter Schlemmer
- From the Department of Neuroradiology (A.R., R.H., L.D.W., P.K., M.B.) and Neurology Clinic (W.W.), University of Heidelberg Medical Center, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany; Department of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany (A.R., R.H., L.D.W., H.P.S.); German Cancer Consortium (DKTK), Heidelberg, Germany (A.R., R.H., L.D.W.); Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University Duisburg-Essen, Essen, Germany (A.R.); and Department of Psychology, University of Mannheim, Mannheim, Germany (P.J.K.)
| | - Martin Bendszus
- From the Department of Neuroradiology (A.R., R.H., L.D.W., P.K., M.B.) and Neurology Clinic (W.W.), University of Heidelberg Medical Center, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany; Department of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany (A.R., R.H., L.D.W., H.P.S.); German Cancer Consortium (DKTK), Heidelberg, Germany (A.R., R.H., L.D.W.); Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University Duisburg-Essen, Essen, Germany (A.R.); and Department of Psychology, University of Mannheim, Mannheim, Germany (P.J.K.)
| |
Collapse
|
8
|
Ramalho J, Ramalho M, AlObaidy M, Semelka RC. Technical aspects of MRI signal change quantification after gadolinium-based contrast agents' administration. Magn Reson Imaging 2016; 34:1355-1358. [PMID: 27693606 DOI: 10.1016/j.mri.2016.09.004] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2016] [Accepted: 09/21/2016] [Indexed: 01/27/2023]
Abstract
Over the last 2years several studies have been published regarding gadolinium deposition in brain structures in patients with normal renal function after repeated administrations of gadolinium-based contrast agents (GBCAs). Most of the publications are magnetic resonance imaging (MRI) based retrospective studies, where gadolinium deposition may be indirectly measured by evaluating changes in T1 signal intensity (SI) in brain tissue, particularly in the dentate nucleus (DN) and/or globus pallidi (GP). The direct correlation between T1 signal changes and gadolinium deposition was validated by human pathology studies. However, the variability of the MR equipment and parameters used across different publications, along with the inherent limitations of MRI to assess gadolinium in human tissues should be acknowledged when interpreting those studies. Nevertheless, MRI studies remain essential regarding gadolinium bio-distribution knowledge. The aim of this paper is to overview current knowledge of technical aspects of T1 signal intensity evaluation by MRI and describe confounding factors, with the intention to achieve higher accuracy and maximize reproducibility.
Collapse
Affiliation(s)
- Joana Ramalho
- Department of Radiology, University of North Carolina, Chapel Hill, North Carolina, United States; Department of Radiology, Centro Hospitalar de Lisboa Central, Lisbon, Portugal.
| | - Miguel Ramalho
- Department of Radiology, University of North Carolina, Chapel Hill, North Carolina, United States; Department of Radiology, Hospital Garcia de Orta, Almada, Portugal.
| | - Mamdoh AlObaidy
- Department of Radiology, University of North Carolina, Chapel Hill, North Carolina, United States; Department of Radiology, King Faisal Specialist Hospital & Research Center, Riyadh. Saudi Arabia.
| | - Richard C Semelka
- Department of Radiology, University of North Carolina, Chapel Hill, North Carolina, United States.
| |
Collapse
|
9
|
Stojanov D, Aracki-Trenkic A, Benedeto-Stojanov D. Gadolinium deposition within the dentate nucleus and globus pallidus after repeated administrations of gadolinium-based contrast agents-current status. Neuroradiology 2016; 58:433-41. [PMID: 26873830 DOI: 10.1007/s00234-016-1658-1] [Citation(s) in RCA: 91] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2015] [Accepted: 02/02/2016] [Indexed: 12/14/2022]
Abstract
INTRODUCTION Gadolinium-based contrast agents (GBCAs) have been used clinically since 1988 for contrast-enhanced magnetic resonance imaging (CE-MRI). Generally, GBCAs are considered to have an excellent safety profile. However, GBCA administration has been associated with increased occurrence of nephrogenic systemic fibrosis (NSF) in patients with severely compromised renal function, and several studies have shown evidence of gadolinium deposition in specific brain structures, the globus pallidus and dentate nucleus, in patients with normal renal function. METHODS Gadolinium deposition in the brain following repeated CE-MRI scans has been demonstrated in patients using T1-weighted unenhanced MRI and inductively coupled plasma mass spectroscopy. Additionally, rodent studies with controlled GBCA administration also resulted in neural gadolinium deposits. RESULTS Repeated GBCA use is associated with gadolinium deposition in the brain. This is especially true with the use of less-stable, linear GBCAs. In spite of increasing evidence of gadolinium deposits in the brains of patients after multiple GBCA administrations, the clinical significance of these deposits continues to be unclear. CONCLUSION Here, we discuss the current state of scientific evidence surrounding gadolinium deposition in the brain following GBCA use, and the potential clinical significance of gadolinium deposition. There is considerable need for further research, both to understand the mechanism by which gadolinium deposition in the brain occurs and how it affects the patients in which it occurs.
Collapse
Affiliation(s)
- Dragan Stojanov
- Faculty of Medicine, University of Nis, Bul. Dr. Zorana Djindjica 81, Nis, 18000, Serbia.
- Center for Radiology, Clinical Center Nis, Nis, Serbia.
| | | | | |
Collapse
|